Evidence of a drug-drug interaction linked to inhibition of ester hydrolysis by orlistat

Journal of Cardiovascular Pharmacology

Volumn 60, Issue 4, 2012, Pages 390-396

  Bentley, Darren ^a   Young, Anne Marie ^a   Rowell, Lucy ^a   Gross, Günter ^b   Tardio, Joseph ^b   Carlile, David ^a  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

dalcetrapib; ester; interaction; lipase; lipophilicity; orlistat

Indexed keywords

CHOLESTEROL ESTER; DALCETRAPIB; ESTER; TETRAHYDROLIPSTATIN; THIOESTER;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ESTERIFICATION; FEMALE; GASTROINTESTINAL TRACT; HUMAN; HUMAN EXPERIMENT; HYDROLYSIS; LIPOPHILICITY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTI-OBESITY AGENTS; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL AVAILABILITY; CHOLESTEROL ESTER TRANSFER PROTEINS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROLYSIS; LACTONES; MALE; MIDDLE AGED; PRODRUGS; SULFHYDRYL COMPOUNDS; YOUNG ADULT;

EID: 84867743729     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31826731ff     Document Type: Article

References (12)

1. McClendon KS, Riche DM, Uwaifo IG. Orlistat: current status in clinical therapeutics. Expert Opin Drug Saf. 2009;8:727-744.
2. Filippatos TD, Dermemexis CS, Gazi IF, et al. Orlistat-associated adverse effects and drug interactions. A critical review. Drug Saf. 2008;31:53-65.
3. Zhi J. Modeling the relationship between drug lipophilicity and potential for an interaction with orlistat. J Clin Pharmacol. 2012;52:595-599.
4. Schwartz GG, Olsson AG, Ballantyne CM, et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009;158:896-901.
5. Roche press release. Available at:http://www.roche.com/media/media- releases/med-cor-2012-05-07.htm. Accessed May 7, 2012.
6. Heinig K, Bucheli F, Kuhlmann O, et al. Determination of dalcetrapib by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2012;66:314-324.
7. Derks M, Kawamura H, Abt M, et al. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, singledose crossover studies in healthy volunteers. Clin Ther. 2011;33:754-765.
8. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline: guideline for good clinical practice. J Postgrad Med. 2001;47:45-50.
9. Haslam DW, James PT. Obesity. Lancet. 2005;366:1197-1209.
10. Hourcade-Potelleret F. Preliminary population PK-PD of dalcetrapib: an agent targeting CETP to raise HDL-C and prevent cardiovascular morbidity and mortality. PAGE. 2010;19:Abstract 1807. Available at: www.page-meeting.org/? abstract=1807. Accessed August 1, 2012.
11. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol. 1996;36:647-653.
12. Fernandez E, Borgstrom B. Intestinal absorption of retinol and retinyl palmitate in the rat: effects of tetrahydrolipstatin. Lipids. 1990;25:549-552.